Skip to main content

Tweets

NEW FROM ACR: Clinical responses with an IL-23i in patients with active PsA See the efficacy and safety data through ~5 years in the RheumNow poster hall. Sponsored by AbbVie Medical Affairs + Health Impact. https://t.co/ZIaGPz7LqO https://t.co/2MEq55tj6c
Dr. John Cush @RheumNow ( View Tweet )
8 hours 1 minute ago
Lupus care is evolving. Two experts explore how updated ACR guidelines meet the real-world challenges of lupus nephritis. Sponsored by Aurinia https://t.co/7NAJW3LoSM https://t.co/UD55QUhUCW
Dr. John Cush @RheumNow ( View Tweet )
9 hours 31 minutes ago
FDA has approved that guselkumab (Tremfya) for the inhibition of progression of structural joint damage in adults with active psoriatic arthritis (PsA) https://t.co/KwcECQpSz1 https://t.co/pSoK930FAX
Dr. John Cush @RheumNow ( View Tweet )
10 hours 40 minutes ago
LRA Awards for Immune Resetting Therapies in Lupus LRA, the world’s largest private funder of lupus research, in collaboration with Genentech, a member of the Roche Group, announced the inaugural recipients of the Lupus Research Alliance-Genentech Award on Immune Resetting https://t.co/eDAq17lhM0
Dr. John Cush @RheumNow ( View Tweet )
13 hours 1 minute ago
Veterans Administration study of 301 #RA pts Rx w/ immune checkpoint inhibitor (ICI) for cancer shows all cause mortality in ICI Rx Cancer pts was no worse when RA pts took ICIs (1.09; 0.94–1.25). Cause of death similar; Infx were rare (<1.0%) https://t.co/3ZYujU5nyE https://t.co/MCDcdWHcVx
Dr. John Cush @RheumNow ( View Tweet )
15 hours ago
Review of Ruxolitinib in 7 pts w/ refractory systemic JIA complicated by macrophage activation (MAS) (ages 1.6-11 yrs; 3M: 4F). 5 achieved complete remission; 2 partial remission. 2 relapsed w/ GC tapering (remission after adding canakinumab). No deaths https://t.co/j4Cm3UYB9c https://t.co/YIupsBank5
Dr. John Cush @RheumNow ( View Tweet )
16 hours 31 minutes ago
Adverse drug events (ADEs) studied in autoimmune rheum Dz (ARDs). In 10,578 ARD pts 30% had 1+ ADE, highest in SSc (36%). Polypharmacy (57.3% minor, 39.4% major) contrib to increasing ADEs. ADEs were more from Sx Rx (antacids, Tylenol, psychotropics) than DMARDs. https://t.co/BOAfU1DyIN
Dr. John Cush @RheumNow ( View Tweet )
18 hours ago
Korean claims data on FX in RA (2010-2017; n = 43,677). RA had more FX (aHR 1.68), regardless of b/tsDMARD use. Seropositive had more Fx (aHR 1.19), Vertebral Fx (aHR 1.4) & hip Fx (aHR 1.55) VS seronegative RA https://t.co/5Fm3o841H7 https://t.co/V0L87JYtba
Dr. John Cush @RheumNow ( View Tweet )
1 day ago
Hopkins study of HCQ in discoid lupus (DLE) - 5 yr outcomes of 106 adult DLE; those on HCQ had less hyperlipidemia (HL), PAD, angina, & CAD. Parallel TriNetX study showed HCQ assoc w/ signif less HTN, HL, DM, CAD, & CVA. https://t.co/yX7FkGCnvR https://t.co/oddq68FYeE
Dr. John Cush @RheumNow ( View Tweet )
1 day ago
WSJ: Nurse Practitioner Is Now the Hottest Job in Healthcare The Wall St. Journal has published a perspective on nurse practitioners (NP) and their very promising careers. https://t.co/YUasxB43ZO https://t.co/tkvKh0JEui
Dr. John Cush @RheumNow ( View Tweet )
1 day ago
Join the global rheumatology community following RheumNow at #EULAR2026 ✔️ Trusted faculty voices ✔️ Fast, curated insights ✔️ Clinically relevant takeaways This is where rheumatology meets real-world practice. https://t.co/Hb88ZCP58P
Dr. John Cush @RheumNow ( View Tweet )
1 day ago
×